MX2020011795A - Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. - Google Patents
Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.Info
- Publication number
- MX2020011795A MX2020011795A MX2020011795A MX2020011795A MX2020011795A MX 2020011795 A MX2020011795 A MX 2020011795A MX 2020011795 A MX2020011795 A MX 2020011795A MX 2020011795 A MX2020011795 A MX 2020011795A MX 2020011795 A MX2020011795 A MX 2020011795A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- combination therapy
- treatment
- antibodies against
- therapy involving
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Abstract
La presente invención proporciona una terapia de combinación para tratar y/o prevenir efectivamente enfermedades asociadas con células que expresan CLDN18.2, que incluyen enfermedades de cáncer tales como cáncer gástrico, cáncer esofágico, cáncer pancreático, cáncer pulmonar, cáncer de ovarios, cáncer de colon, cáncer hepático, cáncer de cabeza-cuello, y cáncer de la vesícula biliar y metástasis de los mismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2012/002211 WO2013174404A1 (en) | 2012-05-23 | 2012-05-23 | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020011795A true MX2020011795A (es) | 2020-12-07 |
Family
ID=48651960
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014014215A MX367241B (es) | 2012-05-23 | 2013-05-21 | Uso de anticuerpos contra claudina 18.2 en una terapia de combinación para el tratamiento de cáncer. |
MX2020011768A MX2020011768A (es) | 2012-05-23 | 2014-11-21 | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. |
MX2020011796A MX2020011796A (es) | 2012-05-23 | 2014-11-21 | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. |
MX2019009441A MX2019009441A (es) | 2012-05-23 | 2014-11-21 | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. |
MX2020011795A MX2020011795A (es) | 2012-05-23 | 2014-11-21 | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014014215A MX367241B (es) | 2012-05-23 | 2013-05-21 | Uso de anticuerpos contra claudina 18.2 en una terapia de combinación para el tratamiento de cáncer. |
MX2020011768A MX2020011768A (es) | 2012-05-23 | 2014-11-21 | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. |
MX2020011796A MX2020011796A (es) | 2012-05-23 | 2014-11-21 | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. |
MX2019009441A MX2019009441A (es) | 2012-05-23 | 2014-11-21 | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. |
Country Status (24)
Country | Link |
---|---|
US (4) | US9433675B2 (es) |
JP (5) | JP6203830B2 (es) |
KR (3) | KR102514338B1 (es) |
CN (3) | CN107050460B (es) |
AR (1) | AR091131A1 (es) |
AU (4) | AU2013265637B8 (es) |
BR (1) | BR112014028941B8 (es) |
CA (1) | CA2874028A1 (es) |
ES (2) | ES2784855T3 (es) |
HK (2) | HK1208151A1 (es) |
HR (1) | HRP20220897T8 (es) |
HU (1) | HUE059241T2 (es) |
IL (2) | IL235672B (es) |
LT (1) | LT3725810T (es) |
MX (5) | MX367241B (es) |
NZ (1) | NZ701575A (es) |
PL (1) | PL3725810T3 (es) |
PT (1) | PT3725810T (es) |
RS (1) | RS63437B1 (es) |
RU (1) | RU2662066C2 (es) |
SG (2) | SG11201406963RA (es) |
SI (1) | SI3725810T1 (es) |
UA (1) | UA115985C2 (es) |
WO (2) | WO2013174404A1 (es) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
WO2010045659A1 (en) | 2008-10-17 | 2010-04-22 | American Gene Technologies International Inc. | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
DK3725810T3 (da) | 2012-05-23 | 2022-07-25 | Astellas Pharma Inc | Kombinationterapi, der involverer antistoffer mod claudin 18.2 til behandling af cancer |
WO2013174404A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
AU2013347184B2 (en) | 2012-11-13 | 2018-06-14 | Astellas Pharma Inc. | Agents for treatment of claudin expressing cancer diseases |
WO2014127785A1 (en) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
WO2014146672A1 (en) | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
WO2016165762A1 (en) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
WO2016165765A1 (en) | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis |
GB201507368D0 (en) * | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
US20180250337A1 (en) * | 2015-09-03 | 2018-09-06 | The Uab Research Foundation | Genetically engineered drug resistant t cells and methods of using the same |
WO2017123918A1 (en) | 2016-01-15 | 2017-07-20 | American Gene Technologies International Inc. | Methods and compositons for the activation of gamma-delta t-cells |
US10767183B2 (en) * | 2016-03-09 | 2020-09-08 | American Gene Technologies International Inc. | Combination vectors and methods for treating cancer |
WO2018009246A1 (en) | 2016-07-08 | 2018-01-11 | American Gene Technologies International Inc. | Hiv pre-immunization and immunotherapy |
EP3487507A4 (en) | 2016-07-21 | 2020-04-08 | American Gene Technologies International, Inc. | VIRAL VECTORS FOR THE TREATMENT OF PARKINSON'S DISEASE |
WO2018187231A2 (en) | 2017-04-03 | 2018-10-11 | American Gene Technologies International Inc. | Compositions and methods for treating phenylketonuria |
CN107177549A (zh) * | 2017-06-29 | 2017-09-19 | 青岛麦迪赛斯医疗技术有限公司 | 一种简单高效的扩增γδT细胞的方法 |
CA3074020A1 (en) * | 2017-09-08 | 2019-03-14 | Phosplatin Therapeutics Llc | Phosphaplatin compounds as immuno-modulatory agents and therapeutic uses thereof |
US11555070B2 (en) * | 2018-03-08 | 2023-01-17 | Phanes Therapeutics, Inc. | Anti-claudin 18.2 antibodies and uses thereof |
TW202003562A (zh) | 2018-03-14 | 2020-01-16 | 中國大陸商北京軒義醫藥科技有限公司 | 抗密連蛋白18.2(cldn18.2)抗體 |
KR20220103820A (ko) * | 2018-05-18 | 2022-07-22 | 라노바 메디신즈 리미티드 컴파니 | 항-클라우딘 18.2 항체 및 이의 사용 |
EP3824096A4 (en) * | 2018-07-18 | 2022-04-20 | AskGene Pharma Inc. | NOVEL ANTIBODIES AND METHODS FOR THE PREPARATION AND USE THEREOF |
JP2021535744A (ja) * | 2018-08-27 | 2021-12-23 | ナンジン・サンホーム・ファーマシューティカル・カンパニー・リミテッドNanjing Sanhome Pharmaceutical Co., Ltd. | 抗クローディン18.2抗体及びその使用 |
WO2020063988A1 (zh) * | 2018-09-30 | 2020-04-02 | 科济生物医药(上海)有限公司 | Cldn18的抗体和化疗药物的联合治疗 |
JP2022506515A (ja) | 2018-11-05 | 2022-01-17 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | 制御性rnaを発現させるためのベクターシステム |
WO2020114480A1 (en) * | 2018-12-07 | 2020-06-11 | Zai Lab (Shanghai) Co., Ltd. | Anti-claudin antibodies and uses thereof |
SG11202106534RA (en) * | 2018-12-28 | 2021-07-29 | Nanjing Genscript Biotech Co Ltd | Claudin18.2 binding moieties and uses thereof |
WO2020135201A1 (zh) * | 2018-12-28 | 2020-07-02 | 四川科伦博泰生物医药股份有限公司 | 一种抗体及其用途 |
EP3902824A4 (en) * | 2018-12-28 | 2023-01-04 | Sparx Therapeutics Inc. | FOR CLAUDIN 18.2 SPECIFIC BINDING MOLECULES, COMPOSITIONS AND METHODS OF TREATMENT OF CANCER AND OTHER DISEASES |
CN116333141A (zh) * | 2019-01-15 | 2023-06-27 | 浙江道尔生物科技有限公司 | 抗cld18a2纳米抗体及其应用 |
CN109762067B (zh) | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
WO2020205331A1 (en) * | 2019-03-29 | 2020-10-08 | Phanes Therapeutics, Inc. | Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof |
CN111944048B (zh) * | 2019-05-16 | 2023-10-03 | 启愈生物技术(上海)有限公司 | 抗cldn抗体及其药物组合物和检测方法 |
KR20220024010A (ko) * | 2019-05-16 | 2022-03-03 | 치루 파머수티컬 컴퍼니 리미티드 | 클라우딘 18a2에 대한 항체 및 그의 용도 |
KR20220012262A (ko) * | 2019-05-24 | 2022-02-03 | 산유 바이오파마슈티컬스 씨오., 엘티디. | 신형 cldn18.2 결합분자 |
EP3929214A4 (en) * | 2019-05-30 | 2022-06-22 | Shandong Boan Biotechnology Co., Ltd. | ANTIBODY OR CHIMERIC ANTIGEN RECEPTOR TARGETING CLAUDIN 18.2 |
WO2021052307A1 (zh) * | 2019-09-16 | 2021-03-25 | 南京圣和药业股份有限公司 | 一种抗b7-h3抗体及其应用 |
CN112707965A (zh) * | 2019-09-30 | 2021-04-27 | 和铂医药(苏州)有限公司 | 靶向cldn18.2的抗体及其制备方法和应用 |
KR20220111308A (ko) | 2019-12-06 | 2022-08-09 | 소티오 바이오테크 에이.에스. | 인간화 cldn18.2 항체 |
WO2021115303A1 (zh) * | 2019-12-11 | 2021-06-17 | 上海复宏汉霖生物技术股份有限公司 | 一种抗Claudin18.2单克隆抗体、其制备方法及用途 |
AU2020410998A1 (en) | 2019-12-23 | 2022-06-16 | Sotio Biotech A.S. | Tumor-specific Claudin 18.2 antibodies |
WO2021129927A1 (en) | 2019-12-23 | 2021-07-01 | Biontech Cell & Gene Therapies Gmbh | Treatment with immune effector cells engineered to express an antigen receptor |
MX2022014332A (es) * | 2020-05-15 | 2022-12-13 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Conjugado anticuerpo-farmaco, metodo de preparacion del mismo y uso del mismo. |
CN111705085B (zh) * | 2020-08-20 | 2020-12-25 | 北京百奥赛图基因生物技术有限公司 | 构建动物模型的方法及应用 |
AU2021345124A1 (en) | 2020-09-16 | 2023-03-30 | Amgen Inc. | Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer |
JP2022061640A (ja) * | 2020-10-07 | 2022-04-19 | 株式会社村田製作所 | 積層セラミックコンデンサ |
WO2022100590A1 (zh) * | 2020-11-10 | 2022-05-19 | 齐鲁制药有限公司 | 针对密蛋白18a2的adcc增强型人源化抗体及其应用 |
WO2022122709A1 (en) | 2020-12-07 | 2022-06-16 | Sotio Biotech A.S. | Antibody-drug conjugates based on humanized cldn18.2 antibodies |
IL302894A (en) | 2020-12-23 | 2023-07-01 | Sotio Biotech A S | CLAUDIN 18.2 tumor-specific antibody-drug conjugates |
WO2023066267A1 (en) * | 2021-10-19 | 2023-04-27 | Biosion Inc. | Antibodies binding cldn18.2 and uses thereof |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
WO2000078961A1 (en) | 1999-06-23 | 2000-12-28 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
NZ531664A (en) | 1998-09-01 | 2005-07-29 | Genentech Inc | Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family |
EP1144629A3 (en) | 1998-09-01 | 2001-11-28 | Genentech, Inc. | Further pro polypeptides and sequences thereof |
CA2343001A1 (en) | 1998-09-16 | 2000-03-23 | Zymogenetics, Inc. | Stomach polypeptide zsig28 |
CA2345377A1 (en) | 1998-10-06 | 2000-04-13 | Curagen Corporation | Novel secreted proteins and polynucleotides encoding them |
CA2383592A1 (en) | 1999-03-31 | 2000-10-05 | Curagen Corporation | 2384891 acids including open reading frames encoding polypeptides; orfx |
EP1208202A2 (en) | 1999-09-01 | 2002-05-29 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6380362B1 (en) | 1999-12-23 | 2002-04-30 | Genesis Research & Development Corporation Ltd. | Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use |
CA2396719A1 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | 22 human secreted proteins |
EP1255864A1 (en) | 2000-01-31 | 2002-11-13 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
WO2001055326A2 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
CA2395858A1 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
AU6802801A (en) | 2000-03-01 | 2001-09-24 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
AU2001260847A1 (en) | 2000-05-24 | 2001-12-03 | Genesis Research And Development Corporation Limited | Compositions isolated from skin cells and methods for their use |
AU8497701A (en) | 2000-08-15 | 2002-02-25 | Immunex Corp | Claudin polypeptides |
WO2002018576A2 (en) | 2000-08-28 | 2002-03-07 | Diadexus, Inc. | Compositions and methods relating to lung specific genes |
AU2001294541A1 (en) | 2000-09-08 | 2002-03-22 | Schering Corporation | Mammalian genes; related reagents and methods |
CN1487996B (zh) | 2000-11-30 | 2010-06-16 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
NZ581541A (en) | 2002-10-17 | 2011-07-29 | Genmab As | Human monoclonal antibodies against CD20 |
DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
US20050181375A1 (en) | 2003-01-10 | 2005-08-18 | Natasha Aziz | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer |
KR20060134216A (ko) * | 2004-04-16 | 2006-12-27 | 에미스페어 테크놀로지스, 인코포레이티드 | 활성제 전달을 위한 8-(2-히드록시페녹시)옥틸디에탄올아민및 그의 염 |
DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
DE102004042822A1 (de) | 2004-08-31 | 2006-03-16 | Technische Universität Dresden | Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen |
EP2182057A1 (en) | 2005-08-31 | 2010-05-05 | Cell Signaling Technology, Inc. | Antibody agains phosphorylated Tyrosine for the detection of protein phosphorylation in carcinoma signaling pathways |
KR101419711B1 (ko) * | 2005-09-08 | 2014-07-17 | 가부시키가이샤 메디넷 | 항원제시세포의 활성화 처리방법 |
US20080050726A1 (en) | 2005-09-19 | 2008-02-28 | Yixin Wang | Methods for diagnosing pancreatic cancer |
EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
NZ569204A (en) * | 2005-12-21 | 2012-03-30 | Micromet Ag | Pharmaceutical compositions with resistance to soluble CEA - comprising antibodies that bind to CD3 and CEA |
US20100129929A1 (en) | 2006-07-27 | 2010-05-27 | Roberto Polakewicz | Tyrosine Phosphorylation Sites |
BRPI0807227A2 (pt) | 2007-02-01 | 2019-01-22 | Veridex Llc | métodos e materiais para identificação da origem de um carcinoma de origem primária desconhecida |
EP2145902A3 (en) | 2007-04-19 | 2010-09-29 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
JPWO2008152822A1 (ja) * | 2007-06-15 | 2010-08-26 | 株式会社メディネット | 医薬 |
WO2009008992A2 (en) | 2007-07-06 | 2009-01-15 | Osi Pharmaceuticals Inc. | Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2 |
EP2036987A1 (en) | 2007-09-17 | 2009-03-18 | Siemens Healthcare Diagnostics GmbH | Molecular markers for tumor cell content in tissue samples |
RU2509085C2 (ru) | 2008-01-28 | 2014-03-10 | Медиммун Лимитед | Стабилизированные антитела против ангиопоэтина-2 и их применение |
WO2009148593A1 (en) | 2008-06-02 | 2009-12-10 | Nsabp Foundation, Inc. | Identification and use of prognostic and predictive markers in cancer treatment |
US8445219B2 (en) | 2008-07-25 | 2013-05-21 | Merck Patent Gmbh | Method of determination of receptor binding saturation effected by monoclonal antibodies |
WO2010141093A2 (en) * | 2009-06-04 | 2010-12-09 | The University Of Maryland, Baltimore | Co-signaling methods for treating cancers |
WO2011090005A1 (ja) * | 2010-01-19 | 2011-07-28 | 協和発酵キリン株式会社 | 大腸癌の治療用医薬および治療方法 |
CA2786940C (en) | 2010-03-16 | 2019-09-24 | Biontech Ag | Tumor vaccination involving a humoral immune response, and proteins therefor including all or a portion of a hepatitis b virus core antigen protein and an epitope of claudin 18.2 |
CN102168067B (zh) * | 2011-02-11 | 2012-08-29 | 浙江大学 | 一种调节性t细胞的诱导培养方法 |
WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
WO2013174403A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
WO2013174404A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
WO2014127785A1 (en) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
JP6241403B2 (ja) | 2014-10-24 | 2017-12-06 | 横浜ゴム株式会社 | リン酸変性ポリマー |
-
2012
- 2012-05-23 WO PCT/EP2012/002211 patent/WO2013174404A1/en active Application Filing
-
2013
- 2013-05-21 SI SI201332002T patent/SI3725810T1/sl unknown
- 2013-05-21 SG SG11201406963RA patent/SG11201406963RA/en unknown
- 2013-05-21 KR KR1020207034499A patent/KR102514338B1/ko active IP Right Grant
- 2013-05-21 KR KR1020147036039A patent/KR102188001B1/ko active IP Right Grant
- 2013-05-21 LT LTEP20163993.7T patent/LT3725810T/lt unknown
- 2013-05-21 NZ NZ701575A patent/NZ701575A/en unknown
- 2013-05-21 US US14/401,557 patent/US9433675B2/en active Active
- 2013-05-21 CN CN201611203411.6A patent/CN107050460B/zh active Active
- 2013-05-21 CA CA2874028A patent/CA2874028A1/en active Pending
- 2013-05-21 JP JP2015513043A patent/JP6203830B2/ja active Active
- 2013-05-21 WO PCT/EP2013/001503 patent/WO2013174509A1/en active Application Filing
- 2013-05-21 ES ES13729591T patent/ES2784855T3/es active Active
- 2013-05-21 HU HUE20163993A patent/HUE059241T2/hu unknown
- 2013-05-21 PT PT201639937T patent/PT3725810T/pt unknown
- 2013-05-21 CN CN201611203370.0A patent/CN107412773B/zh active Active
- 2013-05-21 RS RS20220682A patent/RS63437B1/sr unknown
- 2013-05-21 SG SG10201609510UA patent/SG10201609510UA/en unknown
- 2013-05-21 AU AU2013265637A patent/AU2013265637B8/en active Active
- 2013-05-21 ES ES20163993T patent/ES2924023T3/es active Active
- 2013-05-21 PL PL20163993.7T patent/PL3725810T3/pl unknown
- 2013-05-21 BR BR112014028941A patent/BR112014028941B8/pt active IP Right Grant
- 2013-05-21 UA UAA201413807A patent/UA115985C2/uk unknown
- 2013-05-21 MX MX2014014215A patent/MX367241B/es active IP Right Grant
- 2013-05-21 RU RU2014152107A patent/RU2662066C2/ru active
- 2013-05-21 KR KR1020237009833A patent/KR20230047493A/ko not_active Application Discontinuation
- 2013-05-21 HR HRP20220897TT patent/HRP20220897T8/hr unknown
- 2013-05-21 CN CN201380026898.3A patent/CN104427999B/zh active Active
- 2013-05-22 AR ARP130101785A patent/AR091131A1/es not_active Application Discontinuation
-
2014
- 2014-11-13 IL IL235672A patent/IL235672B/en active IP Right Grant
- 2014-11-21 MX MX2020011768A patent/MX2020011768A/es unknown
- 2014-11-21 MX MX2020011796A patent/MX2020011796A/es unknown
- 2014-11-21 MX MX2019009441A patent/MX2019009441A/es unknown
- 2014-11-21 MX MX2020011795A patent/MX2020011795A/es unknown
-
2015
- 2015-09-07 HK HK15108681.0A patent/HK1208151A1/xx unknown
-
2016
- 2016-08-08 US US15/231,185 patent/US10022444B2/en active Active
-
2017
- 2017-08-30 JP JP2017165302A patent/JP6490763B2/ja active Active
-
2018
- 2018-03-15 AU AU2018201856A patent/AU2018201856B2/en active Active
- 2018-05-07 US US15/973,116 patent/US10813996B2/en active Active
- 2018-05-31 HK HK18107123.5A patent/HK1247567A1/zh unknown
-
2019
- 2019-02-27 JP JP2019034057A patent/JP6833885B2/ja active Active
-
2020
- 2020-05-29 AU AU2020203557A patent/AU2020203557A1/en not_active Abandoned
- 2020-08-02 IL IL276434A patent/IL276434A/en unknown
- 2020-08-31 US US17/008,316 patent/US20200390887A1/en active Pending
-
2021
- 2021-02-03 JP JP2021015688A patent/JP7204791B2/ja active Active
-
2022
- 2022-12-28 JP JP2022212169A patent/JP2023038230A/ja active Pending
-
2023
- 2023-02-08 AU AU2023200682A patent/AU2023200682A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020011795A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
MX2020011771A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
MX2017013075A (es) | Conjugados de farmaco que comprenden anticuerpos contra claudina 18.2. | |
MX2020011772A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
EP4242236A3 (en) | Monoclonal antibodies against claudin-18 for treatment of cancer | |
CY1123593T1 (el) | Συνδυαστικη θεραπεια που περιλαμβανει αντισωματα κλωντινης 18.2 για τη θεραπεια του καρκινου | |
JOP20220013A1 (ar) | علاج توليفي ينطوي على استخدام الأجسام المضادة ضد claudin 18.2 ومثبطات نقاط الفحص المناعي لعلاج السرطان | |
CR20230450A (es) | Terapia de combinación que implica anticuerpos contra claudina 18.2 para el tratamiento del cáncer |